Timex Group India Ltd leads gainers in 'B' group
S P Apparels Ltd, Aarti Drugs Ltd, Faze Three Ltd and PDS Ltd are among the other gainers in the BSE's 'B' group today, 07 May 2025.
Timex Group India Ltd surged 19.41% to Rs 195.3 at 12:02 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 7.36 lakh shares were traded on the counter so far as against the average daily volumes of 61549 shares in the past one month.
S P Apparels Ltd spiked 17.39% to Rs 857.05. The stock was the second biggest gainer in 'B' group. On the BSE, 60164 shares were traded on the counter so far as against the average daily volumes of 1380 shares in the past one month.
Aarti Drugs Ltd soared 14.94% to Rs 402. The stock was the third biggest gainer in 'B' group. On the BSE, 5.05 lakh shares were traded on the counter so far as against the average daily volumes of 17106 shares in the past one month.
Faze Three Ltd exploded 10.67% to Rs 554.7. The stock was the fourth biggest gainer in 'B' group. On the BSE, 16411 shares were traded on the counter so far as against the average daily volumes of 5797 shares in the past one month.
PDS Ltd gained 9.78% to Rs 408.75. The stock was the fifth biggest gainer in 'B' group. On the BSE, 25852 shares were traded on the counter so far as against the average daily volumes of 3208 shares in the past one month.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
19 minutes ago
- The Hindu
Dr. Reddy's Q1 net inches up amid decline in generics sales to U.S.
Generic drugmaker Dr. Reddy's Laboratories' consolidated net profit for the June quarter increased marginally to ₹1,409.9 crore from Rs.1,392.4 crore year earlier as revenue from the all important U.S. market declined amid increased price erosion in certain key products. The net profit came on a more than 11% increase in total revenue from operations to ₹.8,572.1 crore (₹.7,696.1 crore), the results prepared as per Indian Accounting Standards (Ind AS) showed. Pricing pressure on cancer drug Lenalidomide is expected to intensify in the U.S. generics market, according to co-chairman and MD G.V. Prasad. He said this reaffirming the company's focus on strengthening the base business by delivery of our pipeline assets, improving overall productivity and business development.' On segment revenue, the company said global generics contributed ₹7,573.2 crore (₹.6,892.9 crore), while share of Pharmaceutical Services and Active Ingredients declined to ₹987.4 crore (₹1,047.2 crore). In a release, on the results prepared as per International Financial Reporting Standards (IFRS), Dr. Reddy's said revenue from the North America generics market at ₹3,410 crore was 11% lower a decline YoY of and 4% QoQ. The decline was primarily due to increased price erosion in certain key products, including Lenalidomide. Revenue from generics sales in Europe, India and Emerging Markets were higher year on year. The company's shares closed less than 1% higher at ₹1,247.55 each on the BSE.
Time of India
19 minutes ago
- Time of India
Explained: Planning a trip to the US? Get ready to pay more than double visa fees
Explained: Planning a trip to the US? Get ready to pay more than double visa fees Team TOI Plus Jul 23, 2025, 18:37 IST IST Your visit to the US is about to get costlier with the Trump administration set to introduce a new 'visa integrity fee' in addition to the existing fee for all non-immigrant visas. Here's what you need to know and how much it will cost you Planning to visit the United States? It's likely to cost you an extra $250 or approximately Rs 22,000 - for Indians, that means paying more than double the existing visa fee.
Hans India
19 minutes ago
- Hans India
Aditya Birla Real Estate clocks Rs 27 crore loss in Q1, income falls over 55 pc
Mumbai: Aditya Birla Real Estate Limited (ABREL) on Wednesday reported a net loss of Rs 27.08 crore for the first quarter of the current financial year ( Q1 FY26). This marks a sharp reversal from the Rs 17.35 crore profit the company had recorded during the same period previous fiscal, according to its regulatory filing. The company's total income fell 56.9 per cent to Rs 157.41 crore in Q1 FY26, down from Rs 365.24 crore in the April–June quarter of FY25. During the quarter, ABREL reported a loss of Rs 47.30 crore from continued operations, while it registered a profit of Rs 20.22 crore from discontinued operations. The company recently exited its pulp and paper business, previously operated under the Century Pulp and Paper division, as part of its ongoing business restructuring. ABREL, formerly known as Century Textiles and Industries Limited, has also announced plans to raise up to Rs 1,500 crore through secured or unsecured rupee term loans. The fundraising is aimed at refinancing existing debts linked to capital expenditure for its now-sold pulp and paper division. The company said the move will help in releasing charges or encumbrances on the assets of that division, which is being sold to ITC. On the stock market front, Aditya Birla Real Estate shares have seen a 16 per cent decline in the past one month and are down 20 per cent year-to-date (YTD). The stock has fallen 24.85 per cent over the past year. However, over a longer period, the company has delivered strong returns -- rising 150 per cent in the last three years and delivering multi-bagger gains of 560 per cent over five years. At the closing bell, the company's shares were at Rs 2,019, down 5.51 per cent or Rs 117.8 on the National Stock Exchange (NSE) following the announcement of its Q1 results.
